MedTrace Logo

WP1066 in Children With Refractory and Progressive or Recurrent Malignant Brain Tumors

NCT04334863 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2023-02-21

No results posted yet for this study

Summary

In this Phase I clinical study, the investigators plan to offer investigational treatment with the novel JAK2/STAT3 inhibitor WP1066 (Moleculin Biotech, Inc.) to pediatric patients with any progressive or recurrent malignant brain tumor that is refractory to standard treatment and is without known cure.

Conditions

Interventions

DRUG

WP1066

WP1066 is an analogue of caffeic acid that is a potent inhibitor of p-STAT3. It will be taken by mouth 2 times per day on Monday, Wednesday, and Friday of Weeks 1 and 2 of each 28-day cycle.

Sponsors & Collaborators

  • CURE Childhood Cancer, Inc.

    collaborator OTHER

  • Peach Bowl LegACy Fund

    collaborator UNKNOWN

  • Emory University

    lead OTHER

Principal Investigators

  • Tobey MacDonald, MD · Emory University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
3 Years
Max Age
25 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-05-04
Primary Completion
2023-02-03
Completion
2023-02-03
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04334863 on ClinicalTrials.gov